Milner Therapeutics Institute and LifeArc extend strategic partnership
Combines LifeArc’s translational expertise with the Milner’s cutting-edge bioinformatics
Combines LifeArc’s translational expertise with the Milner’s cutting-edge bioinformatics
Funding will accelerate development of new diagnostic tests, treatments, and devices for people with dementia.
LifeArc scientists instrumental to the development of the world’s first anti-IL17BR antibody, now being trialled as a treatment for severe asthma
New, multi-million pound research programme at the University of Edinburgh will develop treatments for lung infections
£1m fund to progress promising translational research addressing a medical need for children and young people
AstraZeneca granted exclusive worldwide licence to develop, manufacture and commercialise RQ Bio’s existing early-stage monoclonal antibodies (mAbs)…
How can we reduce the impact of dementia on individuals, families and wider society?
Melanie Lee on how bringing together diverse teams united under a clear purpose can deliver extraordinary results.
Together with the patient charity Motor Neurone Disease (MND) Association, LifeArc co-sponsored an MND challenge within a…